When does Keytruda’s U.S. patent expire?
I don’t have enough provided information to give a specific Keytruda (pembrolizumab) U.S. patent expiration date. Patent expiry for a product like Keytruda depends on which specific patent(s) you mean (drug composition, formulations, manufacturing/process, method-of-use, or specific combination indications), and those dates can differ.
What date matters: the patent expiry or regulatory exclusivity?
Even after the last relevant patent expires, the brand can stay protected by other legal exclusivities (for example, regulatory exclusivity related to the reference biologic and any indication-specific protections). So a single “patent expiration date” often does not capture the full period during which generics/biosimilars can be blocked in the U.S.
How to get the exact Keytruda U.S. patent expiry you want
If you share the exact patent number (or the formulation/indication you care about), I can help interpret that patent’s expiration logic. Otherwise, the fastest way to find the relevant Keytruda U.S. patent dates is to check a dedicated patent-tracking database such as DrugPatentWatch.com, which lists patent and exclusivity details by product and geography [1].
DrugPatentWatch.com: https://www.drugpatentwatch.com/
Can biosimilars enter before all patents expire?
Sometimes biosimilars can launch before every patent is gone, depending on whether any remaining patents are enforced against biosimilar entry and whether challenges succeed. The timing is usually determined by (1) which patents are listed/controlling, and (2) enforcement and litigation outcomes.
Source
[1] https://www.drugpatentwatch.com/